Biochemist, Biotechnology Expert to Lead C-Path’s Type 1 Diabetes Consortium TUCSON, Ariz., June 2, 2022 — Critical Path Institute (C-Path) has named Elnaz Atabakhsh, Ph.D., as Executive Director of its Ty
FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data TUCSON, Ariz., May 23, 2022 — The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments
May 18, 2022 View Now: Generating Synthetic Longitudinal Data presented by Replica Analytics In this webinar, Replica Analytics’ Dr. Khaled El Emam is joined by Director of Data Science Lucy Mosquera to provide a gene
May 23, 2022-February 8, 2024 View Now | International 2022 Drug-induced Kidney Injury Biomarker Workshop On May 23-24, 2022, the Critical Path Institute hosted the International Drug-induced Kidney Injury Biomarker Workshop. In collabo
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today announced that the E
C-Path and Tufts Medical Center Collaborate on EHR Data Transfer The endeavor represents a major milestone for C-Path TUCSON, Ariz., March 10, 2022 — Critical Path Institute (C-Path) and
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseas
November 16, 2021-November 18, 2021 CDRC 2021 Annual Meeting C-Path’s Cure Drug Repurposing Collaboratory will host a three-day annual meeting in a virtual format, November 16-18, 2021. Tog
C-Path and Cure Mito Announce Data Sharing Agreement to Support Treatment Development For Leigh Syndrome and Mitochondrial Disease TUCSON, Ariz., November 9, 2021 — Critical Path Institute (C-Path) and Cure Mito Foundation (Cure Mito) today announced a joint
C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials Tools being developed by C-Path’s CURE Drug Repurposing Collaboratory will help incorporate adaptive platform trial protocol